The US FDA has granted premarket approval (PMA) for Ethicon’s Omnex surgical sealant, the firm’s first synthetic sealant. The product is designed to stop bleeding during vascular reconstructions by mechanically sealing leaks. Omnex is two to four times as strong as other surgical sealants, Ethicon, a Johnson & Johnson subsidiary, claims. It is also ready to use in less than 30 seconds and is compatible with expanded polytetrafluoroethylene grafts, the Somerville, New Jersey firm added. A 151-patient study has found that Omnex stopped bleeding faster than oxidised regenerated cellulose, another type of sealant (1.99 minutes versus 6.73 minutes, respectively). Omnex is intended for use as an adjunctive sealant and is not recommended in place of sutures, staples, or mechanical closure.
FDA approves Ethicon’s first synthetic internal sealant
The US FDA has granted premarket approval (PMA) for Ethicon’s Omnex surgical sealant, the firm’s first synthetic sealant. The product is designed to stop bleeding during vascular reconstructions by mechanically sealing leaks. Omnex is two to four times as strong as other surgical sealants, Ethicon, a Johnson & Johnson subsidiary, claims. It is also ready to use in less than 30 seconds and is compatible with expanded polytetrafluoroethylene grafts, the Somerville, New Jersey firm added. A 151-patient study has found that Omnex stopped bleeding faster than oxidised regenerated cellulose, another type of sealant (1.99 minutes versus 6.73 minutes, respectively). Omnex is intended for use as an adjunctive sealant and is not recommended in place of sutures, staples, or mechanical closure.
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.